



## **Supplementary information**

Interferon-independent STING signaling promotes HSV-1 resistance *in vivo*


Yamashiro et al.




**Supplementary Fig. 1.** (related to figure 1). **a**, Creation of STING S365A and **b**,  $\Delta$ CTT mice using CRISPR/Cas9. **c**, Bone marrow derived macrophages (BMM) were stimulated for 6h and TNF- $\alpha$  was measured on the supernatant. **d**, Primary macrophages were transfected with 2'3'cGAMP for 4h and relative expression of *Ifna* was analyzed. **e**, Quantification of LC3II/LC3I ratio from three independent experiments similar to Fig.1d. **f**, Colocalization of DNA and LC3 is increased in WT and S365A cells. Fluorescence images of primary macrophages transfected for 6h with Cy3-labeled DNA and LC3. Images were analyzed by an automated pipeline created on Perkin Elmer Harmony software for colocalization quantification (for more details refer to Methods). Scale bars are 50  $\mu$ m. **g**, BMM were transfected with 2'3'cGAMP for 4h and STING puncta formation (in red) was visualized. Scale bars are 10  $\mu$ m. Images were taken using a Carl Zeiss LSM710 confocal microscope. Representative results of three independent experiments, each yielding similar results. Center and error bars show mean and SEM. Analyzed with one-way ANOVA and Tukey post-test. \*,  $p \leq 0.05$ . ns, not significant. Exact p-values were provided in the Supplementary information.




**Supplementary Fig. 2.** (related to figure 2). Creation of IRF3 deficient mice using CRISPR/Cas9. **a**, CRISPR/Cas9 targeting strategy for IRF3. **b**, Sequencing of the targeted locus resulting in *Irf3*<sup>-/-</sup> mutation. **c**, Immunoblot of MEFs for IRF3. Representative results of two independent experiments **d**, Primary macrophages were transfected with c-di-GMP for 6h and relative expression of *Ifnb* was analyzed. **e**, Mice were aerosol infected with 400 CFU dose of *M. tuberculosis* (Erdman strain). Survival of infected mice. (n=12 mice per genotype) **f**, Bacterial burden from lungs at 21 days post-infection. n=4 mice per genotype. Combined two independent experiments. All mice except C57BL/6J WT were bred in-house. Four independent experiments were performed, each yielding similar results. Center and error bars show mean and SEM. Analyzed with one-way ANOVA and Tukey post-test. \*, p  $\leq$  0.05. ns, not significant. Exact p-values were provided in the Supplementary Information.




**Supplementary Fig. 3.** (related to figure 3). Mice were intravenously infected with  $1 \times 10^6$  PFU of HSV-1 (KOS strain). **a**, Viral titers in the liver at 6 days p.i. **b**, Relative expression of *Ifit1* **c**, *Tnf* and **d**, *Il6* from brains at 3 days p.i. All mice except C57BL/6J WT were bred in-house. **(a)**  $n=3/3/3/3$ , **(b-d)**  $n=4/4/6/6$ . Representative results of five independent experiments, each yielding similar results. Center and error bars show mean and SEM. Analyzed with one-way ANOVA and Tukey post-test. \*\*,  $p \leq 0.005$ ; \*\*\*,  $p \leq 0.0001$ . ns, not significant. Exact p-values were provided in the Supplementary Information.



**Supplementary Fig. 4.** (related to figure 4). Mice were ocular infected with  $1 \times 10^5$  PFU of HSV-1 (strain 17). **a**, Viral titers from eyes washed at 2 days p.i. Combined three independent experiments, each yielding similar results. **b**, Relative expression of *viperin* and **c**, *Tnfa*. All mice except C57BL/6J WT were bred in-house. **(b)**  $n=4/6/6/6$ , **(c)**  $n=6/6/6/6$ . Representative results of three independent experiments, each yielding similar results. Center and error bars show mean and SEM. Analyzed with one-way ANOVA and Tukey post-test. \*,  $p \leq 0.05$ . ns, not significant. Exact p-values were provided in the Supplementary Information.




**Supplementary Fig. 5.** (related to figure 4). Brain cells (neurons and astrocytes) were harvested from P0 pups and infected with HSV-1 (KOS strain) at a MOI 1 for 6h and later were stained for LC3 and HSV-1. **a**, Quantification of colocalization of LC3-HSV-1 in neurons was performed and **b**, Viral titers from supernatants were collected 48h later and quantified by TCID50 assay. **c-d**, Same as a-b, in astrocytes. **e**, Cell lysates were collected at 4h post-infection and immunoblot for LC3 and β-actin was performed. **f**, Bone marrow-derived macrophages were infected with HSV-1 (KOS strain) at MOI of 1 and viral titers were quantified at indicated time points. **g**, Quantification of colocalization of LC3-HSV-1 in bone marrow-derived macrophages was performed. (**b and d**) n=3/3/3. (**a-g**) Representative results from two independent experiments, each yielding similar results. Center and error bars show mean and SEM. Analyzed with one-way ANOVA and Tukey post-test. \*,  $p \leq 0.05$ . ns, not significant. Exact p-values were provided in the Supplemental Information.




**Supplementary Fig. 6.** (related to figure 5). **a**, Mice were ocular infected with  $1 \times 10^5$  PFU of HSV-1 (strain 17) and viral titers measured in the brain 6 days p.i. **b**, BMDMs were transfected with 2'3'cGAMP for 6h and relative expression of *Ifnb* was analyzed. **c**, Mice were ocular infected with  $1 \times 10^5$  PFU of HSV-1 (strain 17) and survival rate and **d**, viral titers measured in the brain stem 6 days p.i. All mice except C57BL/6J WT were bred in-house. **(a)**  $n=3/5$  mice per genotype. Combined results from two independent experiments, each yielding similar results. **(c-d)**  $n=6/2$ . Representative results of two independent experiments, each yielding similar results. Center and error bars show mean and SEM. Analyzed with one-way ANOVA and Tukey post-test. \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.005$ . ns, not significant. Exact p-values were provided in the Supplemental Information.

Figure 1c



Supplemental Figure 2c



Supplemental Figure 5e







Figure 1d



Supplementary Fig 7. Full blots of corresponding figures.

**a****Gating strategy for Figure 2g-i (CBA)****b****Gating strategy for Figure 4g-i (sorted brain cells)**

**Supplementary Fig 8. Gating strategies. a, Gating strategy for CBA analysis.** Beads are selected and analyzed according to APC versus PE staining. Each of the 6 clusters evidenced by APC staining corresponds to one cytokine. Median of intensity of PE staining is plotted to its correspondent standard curve for concentration levels. **b, Gating strategy for sorting of brain cells.** Brains from HSV-1 ocular infected mice were collected on day 3 p.i. and sorted as shown.  $n=3$  mice per genotype. Representative results of three independent experiments, each yielding similar results.

Figure 1				Figure 3				Figure 4				Figure 5						
<b>1a</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>3a</b>	WT-Gt	WT-ΔCTT		<b>4a</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>5a</b>	WT-Gt	WT-S365A	WT-ΔCTT	WT-irf3-/-	WT-Tbk1-/-Tnfr1-/-	
c-di-GMP	0.01336	0.00848	0.00848	day 5	< 0.01	< 0.001		day 6	< 0.001			day 5	< 0.05					
2'3' cGAMP	0.0719	0.0719	0.0719	day 6	< 0.001	< 0.001		day 7	< 0.001	< 0.01	< 0.01	day 6	< 0.05		< 0.01	< 0.01	< 0.05	
dsDNA	0.0208	0.0208	0.0208	day 7	< 0.001	< 0.001		day 8	< 0.001	< 0.001	< 0.01	day 7		< 0.01	< 0.001	< 0.001		
				day 8	< 0.001	< 0.001		day 9		< 0.001		day 8		< 0.001	< 0.001	< 0.001		
<b>1b</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>3b</b>	WT-Gt	WT-ΔCTT		<b>4b</b>	WT-Gt	WT-S365A	WT-ΔCTT	day 9		< 0.01				
	0.006	0.0227	0.006	day 5	< 0.05	< 0.001		day 5	0.0082	0.0486	0.0016	day 11		< 0.01				
<b>1f</b>	WT-Gt	WT-ΔCTT		day 6	< 0.001	< 0.001		<b>4c</b>	WT-Gt	WT-ΔCTT		day 12		< 0.01				
	< 0.0001	0.0006		<b>3c</b>	WT-Gt	WT-ΔCTT		day 5	0.0011	0.0467		<b>5b</b>	WT-Gt	WT-ΔCTT	WT-Tbk1-/-Tnfr1-/-			
<b>1g</b>	WT-Gt	WT-ΔCTT		day 6	0.0253	0.0253		<b>4d</b>	WT-Gt	WT-ΔCTT		day 5	0.0027	0.0047	0.0027			
	< 0.0001	< 0.0001		<b>3d</b>	WT-Gt	WT-ΔCTT		day 5	< 0.0001	0.048		<b>5c</b>	WT-Gt	WT-ΔCTT	WT-Tbk1-/-Tnfr1-/-			
<b>1h</b>	WT-Gt	WT-ΔCTT		day 6	0.0459	0.0275		<b>4e</b>	WT-Gt	WT-ΔCTT		day 5	0.0012	0.049	0.049			
	< 0.0001	0.0002		<b>3e</b>	WT-Gt			day 5	0.0059	0.049		<b>5d</b>	WT-Gt	WT-S365A	WT-ΔCTT	WT-irf3-/-	WT-Tbk1-/-Tnfr1-/-	WT-Tnfr1-/-
<b>Suppl 1</b>				day 5	0.0095			<b>4f</b>	WT-Gt	WT-S365A	WT-ΔCTT	day 5	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.002
<b>1c</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>3f</b>	WT-Gt	WT-S365A	WT-ΔCTT	day 5	0.041	0.046	0.048	<b>Suppl 5</b>	WT-Gt					
c-di-GMP	< 0.0001	< 0.0001	< 0.0001	day 5	< 0.0001	< 0.0001	< 0.0001	<b>4g</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>5c</b>	0.0241					
2'3' cGAMP	< 0.0001	< 0.0001	< 0.0001	<b>3g</b>	WT-Gt	WT-S365A	WT-ΔCTT	day 5	0.0383	0.0133	0.0475	<b>Suppl 6</b>						
dsDNA	< 0.0001	< 0.0001	< 0.0001	day 5	< 0.0001	< 0.0001	< 0.0001	<b>4h</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>6a</b>	WT-Gt	Gt-S365A	Gt-irf3-/-	Gt-Tnfr1-/-		
<b>1d</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>Suppl 3</b>				day 5	0.0204	0.0105	0.0094	day 5	0.0115	0.0020	0.0052	0.0106		
	< 0.0001	< 0.0001	< 0.0001	<b>3b</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>4i</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>6b</b>	< 0.0001					
<b>Suppl 2</b>				day 5	0.0054	< 0.0001	< 0.0001	day 5	0.02768	0.02641	0.02641	<b>6c</b>	0.0143					
<b>2d</b>	0.0393			<b>3c</b>	WT-Gt	WT-S365A	WT-ΔCTT	<b>Suppl 4</b>				<b>6d</b>	0.0206					
				day 5	< 0.0001	< 0.0001	< 0.0001	<b>4b</b>	WT-Gt	WT-S365A	WT-ΔCTT							
				<b>3d</b>	WT-Gt	WT-S365A	WT-ΔCTT	day 5	0.0335	0.0488	0.027							
				day 5	< 0.0001	< 0.0001	< 0.0001											

**Table 1: P values for corresponding figures.**